

Notice reference number: 0809.16.07

Notice date: 11/07/2016

What's this about?

Effective date: 13/07/2016

- | | | | | | | |
|---|-------------------------------------|--------------------------------------|--------------------------------|--|-------------------------------|---|
| <input checked="" type="checkbox"/> ASX Trade | <input type="checkbox"/> ASX 24 | <input type="checkbox"/> ASX TECH | | | | |
| <input checked="" type="checkbox"/> Trading | <input type="checkbox"/> Clearing | <input type="checkbox"/> Settlement | <input type="checkbox"/> ALC | <input type="checkbox"/> ASX NET | | |
| <input type="checkbox"/> Operations | <input type="checkbox"/> Technology | <input type="checkbox"/> Market Data | <input type="checkbox"/> Rules | <input checked="" type="checkbox"/> Compliance | <input type="checkbox"/> Risk | <input checked="" type="checkbox"/> Other |

Title

Race Oncology Ltd (previously Coronado Resources Ltd) – Admission and Commencement of Official Quotation

Description

The securities of Race Oncology Ltd (the “Company”) were admitted to the official list of ASX Limited (“ASX”) on Monday, 11 July 2016.

Official quotation of the Company’s securities will commence at 11am AEST (9am WST) on Wednesday, 13 July 2016.

The Company has raised \$4,300,000 under the offer by the issue of 21,500,000 ordinary shares at an issue price of \$0.20 per share.

Quoted securities: 25,346,067 fully paid ordinary shares

ASX Code: RAC

Time: 11:00 AM (AEST)

Date: Wednesday, 13 July 2016

ASX Trade Abbreviation: RACEONCO

ISIN: AU000000RAC3

Home Branch: Perth

Industry Classification: To be advised.

Registered Office: Suite 8, 55 Hampden Road
Nedlands WA 6009

Tel: +61 8 9389 5885

Principal Place of Business: As above.

Company Secretary: Mr Peter Webse and Mr Damon Sweeny (joint company secretaries)

Share Registry: Automic Registry Services
Suite 1a, Level 1, 7 Ventnor Ave
West Perth WA 6005

Tel: +61 8 9324 2099

Fax: +61 8 9321 2337

Email: info@automic.com.au

| | |
|------------------------------|--|
| <u>Balance Date:</u> | 30 June. |
| <u>CHESS:</u> | Participating. The Company will also operate an issuer sponsored sub-register. |
| <u>Dividend Policy:</u> | See section 3.15 on page 13 of the Company's prospectus dated 11 May 2016. |
| <u>Activities:</u> | Development of cancer drug, Bisantrone. |
| <u>Restricted Securities</u> | <p>27,341,434 fully paid ordinary shares, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of quotation.</p> <p>10,000,000 performance shares, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of quotation.</p> <p>9,000,000 options exercisable at \$0.25 and expiring 1 July 2021, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of quotation.</p> <p>10,000,000 options exercisable at \$0.25 and expiring 1 July 2018, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of quotation.</p> |
| <u>Unquoted Securities:</u> | N/A |

What do I need to do and by when?

Instructions

For further details, please refer to the Company's prospectus dated 11 May 2016.

Need more information?

Issued by

Shannon Nicholson

Contact Details

08 9224 0000

Disclaimer